Ru (II) compounds: next-generation anticancer metallotherapeutics?
Metal based therapeutics are a precious class of drugs in oncology research that include
examples of theranostic drugs, which are active in both diagnostic, specifically imaging, and …
examples of theranostic drugs, which are active in both diagnostic, specifically imaging, and …
Ruthenium complexes: an emerging ground to the development of metallopharmaceuticals for cancer therapy
GLOBOCAN 2012 estimates 14.1 million new cancer cases and 8.2 million cancer-related
deaths worldwide. Cancer is rapidly becoming a major public health concern in India as …
deaths worldwide. Cancer is rapidly becoming a major public health concern in India as …
[HTML][HTML] Synthesis, characterization, DNA binding, DNA cleavage, protein binding and cytotoxic activities of Ru (II) complexes
We report on the synthesis of novel Ru (II) compounds (Ru-1 to Ru-8) bearing R-pdc, 4-Cl-
pbinh ligands (where R= 4-CF 3, 4-F, 4-OH pdc= 3-phenyl-5-(1H-pyrrol-2-yl)-4, 5-dihydro …
pbinh ligands (where R= 4-CF 3, 4-F, 4-OH pdc= 3-phenyl-5-(1H-pyrrol-2-yl)-4, 5-dihydro …
Development of arene ruthenium antitumor complexes
W Su, Z Tang, P Li - Mini reviews in medicinal chemistry, 2016 - benthamdirect.com
The organometallic arene ruthenium complexes are rapidly advancing. In particular, the
organoruthenium complexes of the type [(η6-arene) Ru (X)(Y)(Z)] have attracted increasing …
organoruthenium complexes of the type [(η6-arene) Ru (X)(Y)(Z)] have attracted increasing …
Ruthenium (II) complexes as potential apoptosis inducers in chemotherapy
K Zheng, Q Wu, C Wang, W Tan… - Anti-Cancer Agents in …, 2017 - ingentaconnect.com
Herein, the development of ruthenium complexes as potential apoptosis inducers, as well as
their underlying mechanism has been reviewed. In recent years, various ruthenium …
their underlying mechanism has been reviewed. In recent years, various ruthenium …
Novel mononuclear ruthenium (II) compounds in cancer therapy
The present study was conducted to evaluate in vivo anticancer activity of two novel
mononuclear ruthenium (II) compounds, namely Ru (1, 10-phenanthroline) $ _2 $(2-nitro …
mononuclear ruthenium (II) compounds, namely Ru (1, 10-phenanthroline) $ _2 $(2-nitro …
Design, synthesis, characterization, cytotoxic and structure activity relationships of novel Ru (II) complexes
Platinum containing compounds have shown antineoplastic potential, but their clinical
applications have been limited by high toxicity. Ruthenium containing complexes have long …
applications have been limited by high toxicity. Ruthenium containing complexes have long …
Anticancer ruthenium complexes in drug discovery and medicinal chemistry
S Thota - Mini reviews in medicinal chemistry, 2016 - pubmed.ncbi.nlm.nih.gov
Editorial: Anticancer Ruthenium Complexes in Drug Discovery and Medicinal Chemistry
Editorial: Anticancer Ruthenium Complexes in Drug Discovery and Medicinal Chemistry Mini …
Editorial: Anticancer Ruthenium Complexes in Drug Discovery and Medicinal Chemistry Mini …
Arene ruthenium (II) complexes: The promising chemotherapeutic agent in inhibiting the proliferation, migration and invasion
K Zheng, Q Wu, Y Ding, W Mei - Mini Reviews in Medicinal …, 2016 - ingentaconnect.com
Arene ruthenium (II) complexes have been widely investigated as one of the most promising
candidates in chemotherapy because of their low toxicity and high inhibiting activity against …
candidates in chemotherapy because of their low toxicity and high inhibiting activity against …
Synthesis, spectroscopic characterization, in vitro cytotoxic and structure activity relationships of some mononuclear Ru(II) complexes
S Thota, S Vallala, M Imran, S Mekala… - Journal of …, 2013 - Taylor & Francis
New mononuclear Ru (II) complexes [Ru (A) 2 (B)] 2+, where A= 2, 2′-bipyridine/1, 10-
phenanthroline and B= 3, 4, 5-tri-OCH3-DPC, 4-CH3-DPC, 4-N (CH3) 2-DPC, 4-NO2-DPC …
phenanthroline and B= 3, 4, 5-tri-OCH3-DPC, 4-CH3-DPC, 4-N (CH3) 2-DPC, 4-NO2-DPC …